Powered by HealthTechMovers.com
We added 5 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
CVS Health, CVS
Summary: CVS Health Corporation is a pharmacy innovation company. Its offerings include pharmacy benefit management services, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. CVS Health Corporation, formerly known as CVS Caremark Corporation, is headquartered in Woonsocket, Rhode Island.
- Last Price: $72.44
- Price Change: -$0.65, -0.89%
- Yearly Gain: -11.30%
- Market Cap: $94.06B
- P/E Ratio: 11.024
Here are 3rd party ratings for CVS:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 43% (108 out of 250)
What is the sentiment on the street regarding CVS Health ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Very Positive
If you are interested in CVS or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CVS before you decide to make any investment.
Click here for chart >>
Arcus Biosciences, RCUS
Summary: Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
- Last Price: $15.22
- Price Change: $0.26, 1.74%
- Yearly Gain: -29.00%
- Market Cap: $1.12B
- P/E Ratio: -3.738
Here are 3rd party ratings for RCUS:
- TipRanks.com: Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 36% (91 out of 250)
What is the sentiment on the street regarding Arcus Biosciences ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: High
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Very Positive
If you are interested in RCUS or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on RCUS before you decide to make any investment.
Click here for chart >>
Verve Therapeutics, VERV
Summary: Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE, Mass.
- Last Price: $10.81
- Price Change: -$0.20, -1.82%
- Yearly Gain: -51.22%
- Market Cap: $864.83M
- P/E Ratio: -3.546
Here are 3rd party ratings for VERV:
- TipRanks.com: Buy
- TradingView.com: sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Sell, Top 34% (85 out of 250)
What is the sentiment on the street regarding Verve Therapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in VERV or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on VERV before you decide to make any investment.
Click here for chart >>
Olema Pharmaceuticals, OLMA
Summary: Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California.
- Last Price: $15.05
- Price Change: -$0.18, -1.18%
- Yearly Gain: 236.20%
- Market Cap: $834.14M
- P/E Ratio: -6.553
Here are 3rd party ratings for OLMA:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 36% (91 out of 250)
What is the sentiment on the street regarding Olema Pharmaceuticals ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: High
- Insider Signal: Neutral
- Investor Sentiment: Very Positive
- Hedge Fund signal: Positive
If you are interested in OLMA or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on OLMA before you decide to make any investment.
Click here for chart >>
Cormedix, CRMD
Summary: CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog
- Last Price: $2.98
- Price Change: -$0.12, -3.87%
- Yearly Gain: -30.49%
- Market Cap: $169.92M
- P/E Ratio: -3.618
Here are 3rd party ratings for CRMD:
- TipRanks.com: Buy
- TradingView.com: sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 36% (91 out of 250)
What is the sentiment on the street regarding Cormedix ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Very High
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Neutral
If you are interested in CRMD or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CRMD before you decide to make any investment.
Click here for chart >>
Thanks for reading!